Adaptive biotechnologies stock.
Ms. Taylor ADPT stock SEC Form 4 insiders trading. Stacy has made over 25 trades of the Adaptive Biotechnologies stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 18,878 units of ADPT stock worth $162,162 on 6 March 2023.. The largest trade she's ever made was exercising 19,580 units of Adaptive …
ADPT Earnings Date and Information. Adaptive Biotechnologies last announced its earnings data on November 9th, 2023. The reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.03. The business earned $37.92 million during the quarter, compared to analyst estimates of $43.26 million.The growth-stock investor added to her stakes in UiPath (PATH 26.72%), Prime Medicine (PRME 11.02%), and Adaptive Biotechnologies (ADPT 7.31%) on Thursday. What does Wood see in these three ...About Adaptive Biotechnologies Stock. Adaptive Biotechnologies aims to help scientists look at the immune system in a new way, with a combination of DNA sequencing and high-powered computation, to analyze the DNA sequences that make up the immune system. Unlike other cell types, which operate on a fixed set of code from the human genome, immune ... Adaptive Biotechnologies Corp. ( NASDAQ: ADPT) stock is down over 72% in the previous 52-weeks and 58.5% YTD. Since its inception, the company has been a loss-maker. Still, the revenues have been ...Scroll through Adaptive Biotechnologies’ timeline and learn how we have arrived at the precipice of transforming medicine. Our milestones show how we are harnessing the natural capabilities of the immune system to develop clinical …
Dec 1, 2023 · Adaptive Biotechnologies - ADPT - Stock Price Today - Zacks Adaptive Biotechnologies (ADPT) (Delayed Data from NSDQ) $4.37 USD +0.12 (2.82%) Updated Nov 24, 2023 12:59 PM ET After-Market:... Adaptive Biotechnologies Corporation announced a multi-year, global translational collaboration with BeiGene to assess minimal residual disease using clonoSEQ assay technology across the company's... 9db0a67e808.iuF5UsgyO_ajPyA0evrp3ms_tEK0Phtld4MZtKLQRYA.s5AxE5BLZIyTRkdbAM_RlAUMgiTSCiwVG9Z-g9qmC-LO2DMmgwtVt-VZbQIf you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.
Adaptive Biotechnologies shares are trading down 2.6% at $37.12 at the time of this writing on Monday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete ...
THOUSAND OAKS, Calif., and SEATTLE, April 2, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies (NASDAQ:ADPT) today announced a collaboration aimed at helping address the COVID-19 pandemic. The companies will combine expertise to discover and develop fully human neutralizing …Adaptive Biotechnologies Corporation announced a multi-year, global translational collaboration with BeiGene to assess minimal residual disease using clonoSEQ assay technology across the company's... 9db0a67e808.iuF5UsgyO_ajPyA0evrp3ms_tEK0Phtld4MZtKLQRYA.s5AxE5BLZIyTRkdbAM_RlAUMgiTSCiwVG9Z-g9qmC-LO2DMmgwtVt-VZbQAdaptive Biotechnologies announced its first quarter earnings Wednesday, ... Adaptive’s stock value at market close Wednesday was $9.25, down from its high in February 2021 of nearly $70.Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 24.32% and 1.17%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for ...If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.
Mar 24, 2023 · As of March 24, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.43. Adaptive Biotechnologies Corp is up 7.53% from its previous closing price of $7.84. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.79 and $8.24. Currently, there are 143.06 million shares of Adaptive ...
Hardly a day in March has gone by without Wood making purchases of Adaptive Biotechnologies (ADPT 7.31%), Burning Rock Biotech (BNR-0.12%), or both. ... Get stock recommendations, portfolio ...
Scroll through Adaptive Biotechnologies’ timeline and learn how we have arrived at the precipice of transforming medicine. Our milestones show how we are harnessing the natural capabilities of the immune system to develop clinical …Oct 19, 2023 · Adaptive Biotechnologies Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Adaptive Biotechnologies Corp’s trailing 12-month revenue is $189.6 million with a -100.7% profit margin. Year-over-year quarterly sales growth most recently was 11.9%. Nov 30, 2023 · The stock price for . Adaptive Biotechnologies (NASDAQ: ADPT) is $4.4 last updated Today at November 30, 2023 at 9:44 PM UTC. Q Does Adaptive Biotechnologies (ADPT) pay a dividend? Adaptive Biotechnologies (ADPT) Stock Forecast & Price TargetSep 30, 2022 · 2022 Financial Guidance. Adaptive Biotechnologies narrows full year 2022 revenue to be in the range of $185 million to $190 million compared to the previous expectation of $185 million to $195 million. We now expect full year 2022 operating expenses to be below $400 million compared to the previous expectation of between $410 million and $415 ...
Discover historical prices for ADPT stock on Yahoo Finance. View daily, weekly or monthly format back to when Adaptive Biotechnologies Corporation stock was issued.SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...Adaptive Biotechnologies is a biotechnology company that develops products based on the adaptive immune system. The web page provides stock …Taking the right travel adapter with you will ensure you're never without — but with so many types, it can be tricky to know what you need. We may be compensated when you click on product links, such as credit cards, from one or more of our...Dec 1, 2022 · SEATTLE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of its clonoSEQ ® Assay to detect minimal residual disease ... The latest closing stock price for Adaptive Biotechnologies as of November 24, 2023 is 4.37. The all-time high Adaptive Biotechnologies stock closing price was 67.74 on …
Jun 2, 2023 · SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral and poster presentations investigating the clinical ...
Employment: Adaptive Biotechnologies. Stock and Other Ownership Interests: Adaptive Biotechnologies. Maneesh Tandon. Employment: Roche (I) Stock and Other Ownership Interests: Roche Pharma AG. Anna-Maria Fink. Research Funding: Celgene/Bristol Myers Squibb (Inst), AstraZeneca (Inst)Nov 7, 2023 · SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess ... Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...Adaptive common stock is expected to begin trading on The Nasdaq Global Select Market on June 27, 2019, under the ticker symbol “ADPT.” The offering is expected to close on July 1, 2019, subject to the satisfaction of customary closing conditions. ... About Adaptive Biotechnologies2009. 790. Chad Robins. https://www.adaptivebiotech.com. Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions ...Biotech stocks rose Thursday as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10.1 billion. Shares of ImmunoGen closed nearly 83% …Adaptive Biotechnologies Corp is down 12.44% from its previous closing price of $7.96. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.87 and $8.10. Currently, there are 143.51 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive Biotechnologies Corp’s ...
Adaptive Biotechnologies. Cathie Wood has bought almost 10 million shares of this stock for her Ark Genomic Revolution fund. Adaptive Biotechnologies Corp. ( NASDAQ: ADPT ) is a commercial-stage ...
The latest Adaptive Biotechnologies Corporation Registered Shs stock prices, stock quotes, news, and ADPT history to help you invest and trade smarter.
Adaptive Biotechnologies Corp is down 12.44% from its previous closing price of $7.96. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.87 and $8.10. Currently, there are 143.51 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive Biotechnologies Corp’s ...Adaptive Biotechnologies is forecast to grow earnings and revenue by 18.8% and 23.1% per annum respectively. EPS is expected to grow by 21.8% per annum. Return on equity is forecast to be -56.8% in 3 years.SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter of 2023 …Stock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and …Dec 1, 2023 · A high-level overview of Adaptive Biotechnologies Corporation (ADPT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Jun 2, 2023 · Wood has been adding to Adaptive Biotechnologies -- with a market cap barely above $1 billion -- in recent days. Homing in on immune-system genetic sequencing technology, Adaptive hasn't had a ... Dec 4, 2023 · The consensus among analysts is that Adaptive Biotechnologies Corp (ADPT) is an Overweight stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. Biotechnology is a rapidly evolving field that combines biology and technology to develop innovative solutions for various industries. Pursuing a B Tech in Biotechnology can open up exciting career opportunities in research, healthcare, agr...Adaptive Biotechnologies Corp (NASDAQ:ADPT) 4.64 Delayed Data As of Nov 29 +0.27 / +6.18% Today’s Change 2.61 Today ||| 52-Week Range 10.79 -39.27% Year-to-Date Quote Profile News Charts...Adaptive Biotechnologies Corporation Registered Shs's market capitalization is $631.55 M by 144.64 M shares outstanding. Adaptive Biotechnologies …
Hardly a day in March has gone by without Wood making purchases of Adaptive Biotechnologies (ADPT 7.31%), Burning Rock Biotech (BNR-0.12%), or both. ... Get stock recommendations, portfolio ...SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess ...Adaptive Biotechnologies Corp stock performance at a glance. Check Adaptive Biotechnologies Corp’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. ADPT Stock Performance. USD USD; Previous close: 4.38: 4.38: Day range: 4.21 - 4.774.21 - 4.77Year range:Description. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual ... Instagram:https://instagram. ttoo stock twitswe stocksbsjobest bond fund Adaptive Biotechnologies announced its first quarter earnings Wednesday, ... Adaptive’s stock value at market close Wednesday was $9.25, down from its high in February 2021 of nearly $70.Real time Adaptive Biotechnologies (ADPT) stock price quote, stock graph, news & analysis. five year us treasury ratetrading view premium SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral and poster presentations investigating the clinical ... free portfolio trackers Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the ...Adaptive Biotechnologies Stock Performance. NASDAQ:ADPT opened at $4.33 on Tuesday. The firm’s fifty day moving average is $4.59 and its two-hundred day moving average is $6.13. Adaptive Biotechnologies Co. has a one year low of $2.61 and a one year high of $10.79. The firm has a market cap of $626.85 million, a price-to …